Role of High Dose Imatinib in BCR/ABLpos/Phpos CML

QR Code

Role of High Dose Imatinib in BCR/ABLpos/Phpos CML

None

Saved in:

Bibliographic Details
Main Authors:	Petzer, Andreas L., Rumpold, Holger
Format:	Electronic Book Chapter
Language:	English
Published:	IntechOpen 2012
Subjects:	Health Sciences
Online Access:	https://www.intechopen.com/chapters/25654
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

De Novo Acquisition of BCR-ABL Mutations for CML Acquired Resistance
by: Chen, WenYong, et al.
Published: (2011)

BCR/ABL1 Extra Fusions in Patients with Chronic Myeloid Leukaemia (CML)
by: Vargas, Maria Teresa
Published: (2011)

3D-QSAR Design of New Bcr-Abl Inhibitors Based on Purine Scaffold and Cytotoxicity Studies on CML Cell Lines Sensitive and Resistant to Imatinib
by: David Cabezas, et al.
Published: (2025-06-01)

The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
by: Anastasia Putri, et al.
Published: (2020-02-01)

The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
by: Anastasia Putri, et al.
Published: (2020-02-01)

ANALYSIS OF RESPONSE TO FIRST-LINE THERAPY WITH IMATINIB IN AZERBAIJANI CML PATIENTS
by: Aypara Hasanova, et al.
Published: (2025-07-01)

Computational Insights into the Polypharmacological Landscape of BCR-ABL Inhibitors: Emphasis on Imatinib and Nilotinib
by: Rima Hajjo, et al.
Published: (2025-06-01)

BCR-ABL gene amplification in patients with chronic myeloid leukemia and imatinib resistance
by: S. I. Kutzev, et al.
Published: (2022-11-01)

Towards the Cure of CML by the Molecular Approach Strategy
by: Cea, Michele, et al.
Published: (2012)

Molecularly Targeted Therapy: Imatinib and Beyond
by: Poklepovic, Andrew, et al.
Published: (2012)

BCR-ABL Hits at Mitosis; Implications for Chromosomal Instability, Aneuploidy and Therapeutic Strategy
by: Piwocka, Katarzyna, et al.
Published: (2011)

Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients
by: Takahashi, Naoto, et al.
Published: (2012)

International CML forum
by: A. G. Turkina
Published: (2022-11-01)

Isolated thrombocytosis with BCR::ABL1 gene rearrangement – a distinct entity or a variant of chronic myelogenous leukemia (CML)? Case report and review of literature
by: Vipulkumar Prajapati, et al.
Published: (2025-09-01)

Drug- Induced Pneumonitis: A Rare Complication of Imatinib Mesylate Therapy in Patients with Chronic Myeloid Leukemia
by: Lazareva, O.V., et al.
Published: (2012)

Nilotinib - new step of success in CML therapy
by: E. G. Lomaia, et al.
Published: (2022-11-01)

Computational and mechanistic studies on the effect of galactoxyloglucan: Imatinib nanoconjugate in imatinib resistant K562 cells
by: Alphy Rose James, et al.
Published: (2017-02-01)

High Dose Rate Endobronchial Brachytherapy in Lung Cancer in Patients with Central Airway Obstruction
by: Santini, Alejandro B., et al.
Published: (2012)

Cumulative Radiation Effective Dose
by: Hayat, Nelofur, et al.
Published: (2012)

The Role of Low-Dose hCG in the Late Follicular Phase of Controlled Ovarian Hyper Stimulation (COH) Protocols
by: Ashrafi, Mahnaz, et al.
Published: (2012)

Characterizing the dynamics of BCR repertoire from repeated influenza vaccination
by: Guoqin Mai, et al.
Published: (2023-12-01)

Imatinib and hypophosphatemia: Case report and review of literature
by: Erdem Şen, et al.
Published: (2017-07-01)

Case Study in Optimal Dosing in Duodenal Ulcer
by: Peace, Karl E.
Published: (2011)

Hepatic Lipid Accumulation by High Cholesterol Diet is Inhibited by the Low Dose Fish Oil in Male C57BL/6J Mice
by: Hirako, Satoshi, et al.
Published: (2012)

Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
by: V. A. Shuvaev, et al.
Published: (2014-07-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

Optimization of Radiation Dose and Image Quality in Cardiac Catheterization Laboratories
by: Dragusin, Octavian, et al.
Published: (2011)

REVERSAL OF ACCELERATED PHASE CML WITH HIGH BLAST COUNT FOLLOWING 5+2 CHEMOTHERAPY AND DASATINIB: A CASE REPORT
by: Büşra Akdoğan, et al.
Published: (2025-07-01)

Treatment efficacy of chronic myeloid leukemia with imatinib in clinical practice
by: A. K. Golenkov, et al.
Published: (2014-07-01)

Dose Calculations of the Ru/Rh-106 CCA and CCB Eyes Applicators
by: Orion, Itzhak, et al.
Published: (2012)

Dose Reduction on Computed Tomography Angiography Using Adaptive Control Techniques
by: Cai, Zhijun, et al.
Published: (2012)

Secondary Analysis of PSA and BCR-Free Survival in Asian Prostate Cancer Patients
by: Gao X, et al.
Published: (2025-06-01)

THE HISTORY OF CHRONIC MYELOID LEUKEMIA (CML): FROM ARSENIC TO TYROSINE KINASE INHIBITORS (TKI)
by: Rüdiger Hehlmann
Published: (2025-07-01)

The effect of ubiquitination and deubiquitination to imatinib resistance in gastrointestinal stromal tumors
by: Huade Huo, et al.
Published: (2025-07-01)

Chronic myeloid leukemia — before and after imatinib (part II)
by: E. G. Lomaia, et al.
Published: (2022-11-01)

Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01)

Chronic myeloid leukemia — before and after imatinib (First part)
by: E. G. Lomaia, et al.
Published: (2022-11-01)

HIV/AIDS Associated Malignant Disorders: Role of Highly Active Antiretroviral Therapy
by: Mayor, Angel, et al.
Published: (2012)

Pharmacokinetics and Metabolized Caroteniods in Liver of Single Dose Administration in Fancy Carp (Cyprinus carpio)
by: Yuangsoi, Bundit
Published: (2012)

Biological Markers of Recurrence and Survival of High-Grade Gliomas: The Role of Hepatocyte Growth Factor
by: García-Navarrete, Roberto, et al.
Published: (2011)